Glenmark Life Sciences Ltd
NSE:GLS
Cash Flow Statement
Cash Flow Statement
Glenmark Life Sciences Ltd
Mar-2022 | Sep-2022 | Mar-2023 | Sep-2023 | Mar-2024 | ||
---|---|---|---|---|---|---|
Operating Cash Flow | ||||||
Net Income |
5 649
|
5 673
|
6 286
|
6 797
|
6 313
|
|
Depreciation & Amortization |
379
|
391
|
421
|
480
|
535
|
|
Other Non-Cash Items |
399
|
40
|
90
|
179
|
378
|
|
Cash Taxes Paid |
1 382
|
1 259
|
1 536
|
1 589
|
1 630
|
|
Cash Interest Paid |
1
|
0
|
0
|
0
|
15
|
|
Change in Working Capital |
(451)
|
(2 248)
|
(3 663)
|
(2 913)
|
(3 091)
|
|
Cash from Operating Activities |
5 976
N/A
|
3 856
-35%
|
3 134
-19%
|
4 543
+45%
|
4 135
-9%
|
|
Investing Cash Flow | ||||||
Capital Expenditures |
(1 322)
|
(1 865)
|
(1 702)
|
(1 319)
|
(1 290)
|
|
Other Items |
99
|
129
|
161
|
160
|
125
|
|
Cash from Investing Activities |
(1 222)
N/A
|
(1 736)
-42%
|
(1 541)
+11%
|
(1 158)
+25%
|
(1 165)
-1%
|
|
Financing Cash Flow | ||||||
Net Issuance of Common Stock |
10 119
|
0
|
0
|
0
|
0
|
|
Net Issuance of Debt |
(9 619)
|
(16)
|
(16)
|
(28)
|
(22)
|
|
Cash Paid for Dividends |
(1 287)
|
(2 573)
|
(3 859)
|
(2 573)
|
(2 757)
|
|
Other |
(1)
|
0
|
(0)
|
0
|
(15)
|
|
Cash from Financing Activities |
(788)
N/A
|
(2 736)
-247%
|
(3 876)
-42%
|
(2 601)
+33%
|
(2 794)
-7%
|
|
Change in Cash | ||||||
Net Change in Cash |
3 966
N/A
|
(617)
N/A
|
(2 283)
-270%
|
784
N/A
|
176
-78%
|
|
Free Cash Flow | ||||||
Free Cash Flow |
4 654
N/A
|
1 991
-57%
|
1 432
-28%
|
3 224
+125%
|
2 845
-12%
|